Overview

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Status:
Completed

Trial end date:
2003-02-01

Target enrollment:

Participant gender:

Summary

The study aims to assess the routes and the extent of metabolism and excretion of YM178 after a single dose of 14C-radiolabeled YM178 administered as a drinking solution in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron